Literature DB >> 12133572

Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats.

Ahmet Ulugol1, Hakan C Karadag, Melek Tamer, Zeki Firat, Aysegul Aslantas, Ismet Dokmeci.   

Abstract

Recent observations suggest the involvement of adenosine in the peripheral antinociceptive effect of amitriptyline in nerve-injury-induced neuropathic pain. The aim of the present investigation was to evaluate, firstly, the peripheral and systemic effects of amitriptyline on tactile allodynia in the streptozotocin (STZ)-induced diabetic rat model of neuropathic pain and, secondly, whether caffeine coadministration affects the actions of amitriptyline. Diabetes was induced by a single intraperitoneal (i.p.) injection of STZ (50 mg/kg), and tactile allodynia was detected by application of von Frey filaments to the ventral surface of the hindpaw. Both systemic (0.5-2.0 mg/kg, i.p.) and peripheral (10-100 nmol, subcutaneously (s.c.)) administration of amitriptyline were found to produce increases in paw withdrawal thresholds, at higher doses. Coadministration of caffeine (5 mg/kg, i.p.; 1500 nmol, s.c.), at doses which produced no effect on its own, partially reversed systemic and local anti-allodynic effects of amitriptyline. These results indicate an anti-allodynic effect of both peripheral and systemic amitriptyline, and suggest the involvement of endogenous adenosine in the action of amitriptyline in this rat model of painful diabetic neuropathy. These data also suggest that topical application of tricyclic antidepressants may be useful in treating neuropathic pain in diabetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133572     DOI: 10.1016/s0304-3940(02)00491-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

2.  Pharmacological treatment of diabetic peripheral neuropathy.

Authors:  Kenneth Cohen; Nataliya Shinkazh; Jerry Frank; Igor Israel; Chris Fellner
Journal:  P T       Date:  2015-06

3.  Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy.

Authors:  N K Katz; J M Ryals; D E Wright
Journal:  Neuroscience       Date:  2014-11-08       Impact factor: 3.590

4.  Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.

Authors:  Cristiano R Jesse; Ethel A Wilhelm; Cristina W Nogueira
Journal:  Psychopharmacology (Berl)       Date:  2010-08-06       Impact factor: 4.530

5.  Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.

Authors:  Ozgur Gunduz; Cagatay Oltulu; Rabia Guven; Dilek Buldum; Ahmet Ulugol
Journal:  Neurol Sci       Date:  2011-09-10       Impact factor: 3.307

Review 6.  Antidepressants for chronic neuropathic pain.

Authors:  Lori Reisner
Journal:  Curr Pain Headache Rep       Date:  2003-02

7.  The anticonvulsant enaminone E139 attenuates paclitaxel-induced neuropathic pain in rodents.

Authors:  Dhandapani Thangamani; Ivan Ogheneochuko Edafiogho; Willias Masocha
Journal:  ScientificWorldJournal       Date:  2013-12-08

8.  Influences of smoking and caffeine consumption on trigeminal pain processing.

Authors:  Dagny Holle; Anke Heber; Steffen Naegel; Hans-Christoph Diener; Zaza Katsarava; Mark Obermann
Journal:  J Headache Pain       Date:  2014-06-13       Impact factor: 7.277

9.  Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System.

Authors:  Eveline Dischkaln Stolz; Paola Fontoura da Costa; Liciane Fernandes Medeiros; Andressa Souza; Ana Maria Oliveira Battastini; Gilsane Lino von Poser; Carla Bonan; Iraci L S Torres; Stela Maris Kuze Rates
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

Review 10.  New treatments for diabetic neuropathy: symptomatic treatments.

Authors:  Singhan T M Krishnan; Gerry Rayman
Journal:  Curr Diab Rep       Date:  2003-12       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.